21.8 C
New York
Monday, June 15, 2026

Tag: TRI

newssourceFORcompanyinformationcontent1marketreleases

Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of...

As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52...

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and...

Implantica announces publication of the landmark RefluxStop® 5-year clinical study results demonstrating excellent long-term success

VADUZ, Liechtenstein, July 1, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of treatment for acid reflux with its unique device...

Magellan Jets Unveils Fractional Ownership Program, Powered by Slate Aviation, with Bombardier Challenger 850

QUINCY, Mass. and WEST PALM BEACH, Fla., June 30, 2025 /PRNewswire/ -- Magellan Jets, a leader in private aviation solutions, today announced the launch of...

InterShunt Enrolls First Patient in New Heart Failure Study

Innovative procedure aims to ease symptoms and reduce hospitalizations MINNEAPOLIS, June 30, 2025 /PRNewswire/ -- InterShunt Technologies, Inc., a medical device company focused on...

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

SELECT MEDICAL SIGNS AGREEMENT WITH BALLAD HEALTH TO OPERATE JOINT VENTURE CRITICAL ILLNESS RECOVERY HOSPITAL

MECHANICSBURG, Pa., June 27, 2025 /PRNewswire/ -- Select Medical Corporation today announced it signed a membership interest purchase agreement with Ballad Health to jointly operate...

GC Biopharma USA Highlights Innovative Manufacturing Approach to IVIG Safety at 2025 CIS Annual Meeting

Differences in manufacturing processes impact the tolerability of intravenous immune globulin (IVIG) products GC Biopharma's manufacturing process reduces FXIa to undetectable levels – a critical...

UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder

Phase 3 study met primary and most key secondary clinical endpointsThis marks the third developmental and epileptic encephalopathies (DEE) population for fenfluramine with positive phase...

Cellarity Initiates Phase 1 Clinical Study of CLY-124, a First-in-Class Globin-Switching Oral Medicine for the Treatment of Sickle Cell Disease

Initiation follows successful IND clearance based on preclinical data package indicating robust increase in fetal hemoglobin with no cytotoxicity Novel Globin-Switching mechanism derived from...

Taiwan’s Solar Festival Invites Canadians to Experience the Island’s Vibrant Summer Celebrations

VANCOUVER, BC, June 25, 2025 /CNW/ -- The Taiwan Tourism Administration is proud to present the 2025 Solar Festival, a series of events celebrating Taiwan's...

BioCity’s ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria

Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal TherapySHANGHAI, June 25, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for...

SKYX Provides Corporate Update, Including its Official Addition to the Russell 2000 on June 27, 2025, and its Expected Deployment of 500,000 Units of...

SKYX Provides Corporate Update

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTRI

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers